Olfactory dysfunction and emotional impairment are nonmotor symptoms in Parkinson disease (PD). These symptoms might be correlated with the appearance of Lewy bodies and neurites (ubiquitin and a-synuclein aggregates) in the amygdala (Braak stage 3). a-Synucleinopathy in the amygdala has been studied only occasionally, and no data on cell types involved are available. This work aimed to analyze a-synuclein expression in the basolateral, central, and cortical amygdaloid nuclei in 5 PD patients (Braak stages 3-5) and 5 controls. Expression of somatostatin and parvalbumin as well as its colocalization with a-synuclein was quantified under confocal microscopy. a-synuclein expression did not differ significantly between the central and other nuclei. The density of somatostatin was significantly decreased in the basolateral and central complex. The density of parvalbumin was significantly diminished in the basolateral complex. Parvalbumin-positive cells colocalized frequently with a-synuclein (68.44%), whereas, somatostatin-positive cells colocalized only occasionally (6.98%). These data revealed the differential vulnerability among interneuron populations in the human amygdala and could help to explain nonmotor symptoms such as anhedonia in PD.
INTRODUCTION
Olfactory dysfunction and emotional impairment are common nonmotor symptoms in Parkinson disease (PD). In fact, olfactory dysfunction and depression (6anxiety) had recently been included for The International Parkinson and Movement Disorders Society Task Force as clinical nonmotor "markers" (1) . These symptoms can precede classical motor features in 2 (anhedonia) to 10 (hyposmia) years and their combination with other nonmotor symptoms increases the capacity to discriminate PD from other disorders (2) . Given that the human amygdala is involved in emotional processing and cognitive functions (3), these symptoms (4) could be associated with amygdaloid a-synucleinopathy (Braak stage 3) (5). There is a relationship between amygdaloid connections (6), cell types involved (7) , and given functions. Glutamatergic principal neurons and inhibitory interneurons, mainly GABAergic, are located in different amygdaloid nuclei. Among GABA-containing interneurons, we have focused on 2 populations: 1 subpopulation that expresses parvalbumin (a calcium-binding protein) (8) and another that expresses the neuropeptide somatostatin (9) . Although the function of these interneurons is not well known, it is proposed that they are involved in reducing the metabolic cost of pumping calcium since the lack of calcium buffer contributes to neuronal vulnerability (10) . To evaluate whether this neuronal vulnerability is due to amygdaloid a-synucleinopathy, brains from PD patients and age-matched controls were analyzed regarding a-synuclein distribution and its colocalization with somatostatin and parvalbumin.
MATERIALS AND METHODS
Ten postmortem pathologically diagnosed amygdalae from PD patients (Braak stages 3-5; n ¼ 5) and controls (n ¼ 5) (Table) C with primary mouse antia-synuclein antibody (1:20, clone KM51; Novocastra, Newcastle, UK) containing 0.3% Triton X-100 (TX-100, Sigma-Aldrich, Madrid, Spain). Subsequently, sections were incubated in secondary biotinylated antimouse antibody (1:200; Vector Laboratories, Burlingame, CA) and in avidin-biotin complex (ABC Standard; Vector Laboratories), and reacted with 0.025% 3.3'-diaminobenzidine (Sigma-Aldrich, Madrid, Spain) and 0.1% H 2 O 2 (Sigma-Aldrich, Madrid, Spain). Sections were mounted, some of them Nissl-counterstained, dried, dehydrated, and coverslipped with DPX (BDH, Poole, UK).
For immunofluorescence procedures, tissue epitope was unmasked and endogenous peroxidase activity inhibited as described above. Sections were incubated for 48 hours at 4 C with primary mouse antia-synuclein antibody (1:20, clone KM51; Novocastra, Newcastle, UK) containing 0.3% TX-100. Subsequently, sections were incubated in secondary fluorescent Alexa 555 donkey antimouse antibody (1:200; Molecular Probes, Eugene, OR). Sections were blocked for 1 hour in 5% normal donkey serum (Sigma-Aldrich, Madrid, Spain) and 0.3% TX-100 in TBS. Sections were incubated overnight at 4 C with primary antibodies: goat antiparvalbumin (1:1000; Swant, Marly, Switzerland) and goat antisomatostatin (1:500; Santa Cruz Biotechnology, Santa Cruz, CA). After 3 washes in TBS (15 minutes each), sections were incubated with the corresponding secondary fluorescent-labeled antibodies for 2 hours: Alexa 488 donkey antirabbit and Alexa 647 donkey antigoat (1:200; Molecular Probes). Finally, sections were counterstained with 4',6-diamidino-2-phenylindole (DAPI), mounted and coverslipped with PVA-DABCO (Sigma-Aldrich, Madrid, Spain).
For quantification, 36 sections of amygdala were analyzed for PD and controls: 18 rostral sections from Bregma 2.7 to 6.7 mm and 18 caudal from 8 to 12 mm (11). Nine pictures (20Â magnification) of each section (3 random pictures per basolateral, central, and cortical nuclei) were captured (n ¼ 324). The images were analyzed with ImageJ and ZEN software avoiding overlapping (LSM 710 Zeiss confocal spectral microscope), using a protocol for semiautomated counting of stained nuclei (12) adapted to our laboratory (13) .
GraphPad Prism version 6 (San Diego, CA) was used for statistical analyses. The Shapiro-Wilk test was carried out to analyze the normality of the sample (p > 0.05). Statistical comparisons were made using two-way ANOVA followed by Bonferroni and Tukey post hoc tests and Kruskal-Wallis followed by Dunn's post hoc tests to estimate the significance of differences between markers, areas and disease. All data are represented as mean 6 SEM. Differences were regarded as statistically significant at *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. 
8-12 mm
All tissues were post-fixed in our laboratory for 45 days in 4% paraformaldehyde. AD, Alzheimer disease; C, Control; no-fix, no fixative was used; PMD, postmortem delay; TAU, tau pathology of neurofibrillary tangles (NFTs).
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RESULTS
The basolateral (basolateral and basomedial nuclei), central, and cortical (anterior and posterior cortical nuclei) groups were delimited by Nissl-staining (images not shown) (11) . Immunohistochemistry revealed that a-synuclein expression was perfectly circumscribed, and delimited each amygdaloid nucleus in all PD cases (Fig. 1A I, II) . For instance, in the central nucleus, numerous Lewy bodies and dystrophic neurites were observed (Fig. 1A, III) , whereas, the posterior cortical amygdaloid nucleus mostly had Lewy bodies (Fig. 1A, IV) . None of the control brains exhibit Lewy bodies and dystrophic neurites in any of the amygdala nuclei (images not shown).
Quantitative immunofluorescence against a-synuclein showed that the protein aggregates, including both Lewy bodies and neurites in the basolateral (Fig. 1B I) , central (Fig. 1B, II) , and cortical (Fig. 1B, III) Double immunofluorescence was used to analyze both the density of somatostatin-positive (Fig. 1C, I -III) or parvalbumin-positive (Fig. 1C , IV-VI) cells and colocalization with a-synuclein (Fig. 1D, I-III) . A two-way ANOVA with disease (control vs PD) and area as factors revealed the following results. The density of somatostatin was significantly decreased in the basolateral and central complex (Area: (Fig. 1C, VI) . The percentage colocalization showed that the majority of parvalbuminpositive cells were associated with a-synuclein aggregates in basolateral and cortical complex, as compared to colocalization of somatostatin and a-synuclein (Kruskal-Wallis statistic 48.21, Dunn's post hoc test, p < 0.0001) (Fig. 1D, I-III) . Parvalbumin-positive cells colocalized 68.44% 6 9.21% with a-synuclein, whereas somatostatin only colocalized 6.98% 6 0.54% (Fig. 1D, I-III) . Linear regression and Spearman q (nonparametric data) were used to analyze these correlations (Supplementary Data Fig. S1 and Table S1 ). Therefore, correlations between disease duration vs a-synuclein density in the basolateral (Supplementary Data Table S1 ). Each graph represent 1 single patient (with different density measures) per disease duration, which should be considered with caution.
DISCUSSION
In agreement with previous reports, the cortical and central nuclei of the amygdala were most severely affected by a-synucleinopathy (5). Other studies have shown that a-synucleinopathy is particularly concentrated in the cortical and basolateral nuclei (4), although most nuclei are differentially involved (14) . Our study in the A53T mouse model of a-synucleinopathy also indicates that the basolateral nucleus is the most severely affected, although the reduction of a-synuclein observed from 43 to 56 weeks (13) is not congruent with the progressive accumulation of this proteinopathy described in humans (15) .
The heterogeneous ontogenetic origin (16) and the high structural (17) and functional (18) complexity of the amygdaloid complex are related to early (hyposmia and dysautonomia) (1, 5) and late (anhedonia) symptoms in PD (4), among others. In accordance with above, and apart from aging alterations (19) , it has been reported a 20% reduction of the total amygdala volume in the number of PD patients that suffer visual hallucinations and depression (4) . Visual hallucinations are related to amygdaloid a-synuclein, but only in those with concomitant dementia (20) . Magnetic resonance studies have reported amygdala atrophy in patients with PD (21) and this reduction is correlated with the impaired recognition of emotions using facial emotional expression (22) . This study is limited by the low number of cases, which makes the cohort not uniform. There are variability among gender ratio (23) , age, postmortem delay, etc. (Table) . This fact adds uncertainty to the cause of somatostatin and parvalbumin density decrease but it is important to note that there is strong colocalization with a-synuclein. Also, the limited clinical information of cases prevents clinic-pathological correlations.
In the present work, we studied the pathology of different amygdaloid nuclei among different neuronal populations. Recent optogenetic experiments have revealed that specific projections from some cells in the basolateral nucleus and somatostatin-positive cells in the central nucleus, which in turn project to the paraventricular nucleus of the thalamus and periaqueductal grey matter, specifically trigger the "fear circuit", and that parvalbumin-positive cells are retroinhibitors in this circuit (7) . In agreement with previous data (24), our present results indicate that somatostatin-positive cells are little affected by a-synuclein and parvalbuminpositive cells are preferentially affected. It is at present unclear, however, to what extent cells containing Lewy bodies were less vulnerable and still alive, whereas, those more vulnerable had already disappeared. Future experiments with apoptotic cell markers are needed. In this sense and in agreement with our results, our data in Alzheimer disease comparing diseased and control brains have revealed a loss of almost 50% expression of somatostatin (25) . Although it was observed a decrease of parvalbumin-positive cells in the present report, as well as in aging (26), in Alzheimer disease the results were the opposite (27) . Therefore, differential vulnerability among interneuron populations should be further analyzed in different neurodegenerative and even concomitant pathologies in order to shed light on neuroprotective mechanisms involved.
